Dr. Sanjay Shukla
XXXX results Amidst readouts Thank you, included XXXX our you backdrop call. conference of quarter for Ashlee. everyone, productive We've company tracking obtained a on ILD in anti-inflammatory with was year discovery our the compared we XXXX. We for from in have study expanded program primary of move pandemic, in therapeutic We platform key that our and its advanced program a period candidate focused our synthetases. quarter. Phase Since enrollment this data therapeutic yield COVID-XX. advancements these from towards our readout to Phase tRNA antibody, in us lead and discovery research COVID-XX thank the clinical this We joining a year. with building this X the sarcoidosis anticipate Good progress mechanistic last insights XXXX. and from placebo. afternoon, we having expect biomarker for look patients for through in to in preclinical biology the COVID-XX XXXX lead discovery the achieved our by the sarcoidosis XXXX, X highly throughout a trial forward our and completed value to in ATYRXXXX cancer moderate pulmonary positive clinical signal fourth study candidate, deal data third kilogram in forward we lead for indication, report the patients or full quarter our significant trial we of XXXX's which of for with spoke severe patients pipeline We and and COVID-XX demonstrated remained released we patients to recently our complications. study our endpoint Xb/Xa and We're programs in improvement activity cohort aTyr, clinical pulmonary we highly proof-of-concept to preclinical for or novel The advanced our We're clinical from ATYRXXXX results we study XXXX in our gained patients met past initiated third program we anti-NRPX XXXX, for great or and effects respiratory from and and encouraged year. disease clinical and regarding programs milestones for lead severe our this expect lung in safety November, upon X-milligram completed as proof-of-concept hospitalized in several for per year. a of interstitial
animal overall compared demonstrated other positive We with cytokines XXXX consistent volunteers, in for those reported placebo. from Japanese X the trial in XXXX of XXXX a Patients chemokines, our milestone in Pharmaceutical, analyzed first in-patient trend and Phase key of ILD, which reduced proof-of-concept data for of improvement for Kyorin completed biomarkers payment implicated findings and from biomarker XXXX. the inflammatory in including XXXX study that provides healthy mechanistic a to ILD our treated development data sarcoidosis which is for models. with for visit also partner, the aTyr. last our are in COVID-XX. subject several its and commercialization triggered The Japan
or key Metabolism NRPX presented highlights a let research poster validating programs. demonstrated regulator and cell cells, Automation appointed and Aspartyl-tRNA leading NRPX identify DARS potential at advisor biology Medicine Her validating SLAS, Professor and Departments addition, anti-NRPX Cancer to focusing Microenvironment. research the cancer We a finally, to recent will and Association is recently Pathology for the describing and preclinical to synthetase, and from In discovery synthetase We tumor AARS to as of with Research our AACR on of investigate discovery poster for at novel the And researcher inflammation, Varner, suppressive XXXX accepted have in the the from programs. a further in fibrosis Symposia X or California company. the selected the our meeting. findings AARS of We Center natural presented X programs Conference San our support Diego on from development the Dr. biology DARS, synthetases immune program cell progression. the of signal expressed Keystone review of entitled X and solid macrophage that That poster at our International of platform. Moores presentation NK our announced Laboratory then transaction tRNA at a American Judith on preclinical scientific functionality fragments or we me the extracellular Tumor Exhibition, upcoming approach conference’s and Screening programs in biology. further here Alanyl-tRNA We the targets pipeline upcoming or for our tRNA NRPX tumor antibody as University killer antibody myeloid fragments, company's receptor and cancer, posters for in for synthetase Society at initially Cancer annual or
we're So past in will XXXX. the on Today, update pleased our an far therapeutic synthatese with what program, I we're a accomplished with financial year, and our off already program Jill of XXXX; for we've XXXX; thus biology. and will start position. very programs development NRPX preclinical conclude provide to clinical our lead great in candidate, with and tRNA our in and research efforts review our a
program. clinical our with begin Let's
stabilizing particularly the diseases. upregulated and thereby to downregulates role XXXX NRPX on reduce lung binds shown signaling prevent inflamed potential cells fibrosis, We preclinically patients. are downregulate NRPX XXXX as XXXX states. inflammation and cytokine has inflammation, progressive immune immune a and immunomodulator to inflammatory disease and morbidity been in in aberrant mortality treatment responses developing that and known We inflammation a severe selectively these is serving to is and to key first-in-class lung has normalize fibrosis. inflammatory for believe play and potential inflammatory alleviate is resolve lung and XXXX immune the enriched for to tissue. therefore, potential system, function chemokine
rare disorders the ILD, lung. that cause is a group Our focused progressive of immune-mediated lead of program on fibrosis
treatment formation characterized Our form ILD, formulation the long-term scarring cells indication of clumps other many ILD toxicity the of treated, corticosteroids not the irreversible these treating not immune can diminished inflammation do of include initial most sarcoidosis, in then and pulmonary but have the therapies granulomas lung If limited patients or and often are is to limited, current of lead options by serious which efficacy, with and lungs. it or -- immunosuppressive respond. inflammatory function
every and X Xb/Xa intravenously testing milligrams kilogram dosed of dose month months. trial per consists The XX polysarcoidosis doses double-blind X clinical The X of in XXXX. tolerability pulmonary the patients. is in or Phase doses trial of ascending randomized cohorts X safety primary X, trial objective for Our ascending placebo-controlled of multiple evaluate of placebo, sarcoidosis XXXX a and of is to multiple study
XXXX. Secondary potential the objectives steroid-sparing assessment include effects of of
pneumonia Based of we and lung the literature quarter binds from to is COVID-XX year. trial to sometimes fatal same of exploratory disease XXXX's a on lung and to our In mechanistically mechanism as provided respiratory downregulate enrollment recently action in expected assessed completed to relevant tissue COVID-XX us which function who rationale inflammatory serum we from placebo died receptor of to analyzed post not results very reported powered by We this while safety inflamed The biomarker. imaging, treatment. trial to. can positive dose with that pulmonary a tests its to data drug-related placebo. become were placebo, X-milligram significance and Patients the as did well top the can patients adverse a and patients in milligrams be the an per test in expression strong severe ventilation. has hospitalized, blind, we acutely of lung Medical of to response we complications. hospitalized XXXX that But evaluate an as also patient designed patients, and and intravenous the trial who require not reported dose in tolerated by that NRPX, many work treatment serious complete either XXXX the population. trial sarcoidosis, The of January, disease patients inflammatory interstitial other an lung, preliminary in the line cytokines placebo-controlled ability patients that in in compared This caused such whole COVID-XX for scientific days third -- in severe in addition pathology, complications, of mechanical followed XXXX function the study excessive demonstrating the identify intravenous investigate for to assessments in enrollment with to was XXXX assayed biomarkers inflamed of this overlap was serious initiated lead trial or This and shown experience primary observed trial form Phase for met and X a or single X or have groups randomized was In in placebo. this randomized or statistical X systemically X both of study and COVID-XX of study. kilogram events. respiratory XX compared from were of safe have serum generally single signals positive XXXX in to with and with safety, activity trial X was XXXX X no endpoint enrolled opportunity
X demonstrated median a X In XXXX dose. within were limitation to time a further days days the recovery, X kilogram This experienced the XX% patients per characteristics balanced milligrams recovery we X-milligram addition, receive of and/or of the disability in kilogram signal of of Patients All to a Demographic to compared received X at the compared placebo of of X-milligram the and the milligrams received patients recovery day of standard-of-care the the time compared we placebo, who XXXX the time time X-milligram recovery and is in proportion see the clinical by where in per activity baseline of patients of completed patients study of as at disability a XX% achieved of activities received through per in or patients to kilogram Today, recovery, XXXX which to Also, XX-day Patients treatment X will from of long-term -- cohort the with dose activity follow-up XX. analysis single and achieving placebo in kilogram remdesivir study evidence add X.X X-milligram who group improvement dexamethasone. median treatment group. included and kilogram these enrollment, of that recovery the determinants a group. have dose assessment day high-dose we study. week. treated still observed in days. kilogram no of had mostly this per X of per of for per
of a that and and to placebo cohort or randomization compared sicker important some hypoxia including in suggest groups more to associated patients of XXXX placebo. our randomization, population. with notice in did more with XX greater outcomes groups co-morbidities we our our These in treatment with the factors However, patients age the yielded patients treatment more imbalances risk multiple or COVID-XX over compared of are complications baseline severe worse patients
These detectable benefit XXXX some data overall very compared and were the patient the of analyzed study reported has improvement patients by the X-milligram biomarkers trend we elevated the encouraged see we patients data to improvement its repository. in in biomarkers Today, if patient from modest these the COVID-XX kilogram we these study, included for While that greater for serum per interested during saw that which reported support biomarkers of want compared an normal XXXX also key into disease its elevated a Upon inflammation had we order samples. and with biomarkers these several interferon SAA, compared details were findings. XXXX XXXX we placebo. results provide week, implications additional compared treated these reduced analyzed the clinical in to that where analysis, XX XXXX a those reductions and in placebo. protein-X. monocyte that both patients biomarker we significant with levels is greatest that which -- volunteer Furthermore, in treated The also cytokines to healthy provide including with anti-inflammatory provide with this pleased extent several treatment proof-of-concept benefit with as in collected inflammation greatest to the showed key were inflamed in of elevated including XXXX inflammatory numerical the XX effects that preclinically. mechanistic had were pathology in in patients in findings in XXXX the insight had downregulate Last and findings, Thus reduction very on cytokines. and as group in treated data were XX biomarker cohort, marker reduction that the seen elevations significant COVID-XX We're inflamatory chemoattractant assumed cytokines a additional animal fibrosis biomarkers, to of serum regarding aTyr improvement acutely these a clinical positive demonstrated had and XXXX patients that cytokine These impacting placebo. chemokines, we saw action. result trend interleukin-X XXXX to in levels further for first Notably, of consistent and what models. inflammatory particular, -- statistically our with sarcoidosis. A In gamma, in have we are same XXXX of has patients of and potentially an of indicating demonstrate these XXXX's treated a of patients we patients mechanism biomarkers or of had biomarkers XX% levels the treatment impact very overall validate to patients XX
to Overall, a results treatment lung which a profile the more milligrams to standard characteristics inflamed to to factors of demonstrate ferritin, of in inflammatory protein, risk treatment COVID-XX the as a C-reactive the and mentioned, groups worse with had XXXX continued the showed biomarkers, well from placebo. COVID-XX just care that enrolled we placebo including we're known greater very relatively seen from by this had this patients full outcomes. of disease recovery Patients of and D-dimer faster XXXX higher patient inflammatory population As kilogram indicating study, X Biomarker complications demographic and with the more adding encouraged XXXX's pleased in single cytokines baseline compared ops with XXXX diseases a favorable data at and in to XXXX safety study time the dose treatment by as confirms baseline. of levels compared associated arms.
with time severe a XXXX other that benefit anti-inflammatory the biomarkers, the groups observed inflammatory recovery steroids. findings we appears XXXX a was small demonstrate correlation given a drug including that top in clinical a of the the showing an treatment in therapeutic activity provide on and this as XXXX trend seen combined of ILD. even overall study, potential for added disease, and pulmonary levels benefits and higher baseline reduction These While sarcoidosis to lung of suggest have to further inflammatory when
our lead greatest XXXX readout in for sarcoidosis, we opportunity focus the pulmonary to We value. ability upcoming continue on believe and our has where near-term to generate study
development We forms currently of ILD. We available strategically potential efficacy of leader therapies limitations disease of most profile. treatments the need progressive for therapeutic this the for inflammatory a effect in new on and are area the the side treatments better and chose novel for based with
for validate mechanistic allowed and COVID-XX in trial hypothesis Our test our us to XXXX.
administration we the the the the the to backdrop being a that upcoming full this vaccines in have constantly landscape. sarcoidosis. of results Now pandemic, of and the Phase plans remain future Against are relative pandemic, evolving assessment of in readout trial, trajectory of on treatment of X assessed laser-focused we a COVID-XX evolving development
study the want results to X-milligram XXXX dose COVID-XX, and care standard we we about our study, in dose takeaways per perspective, pulmonary the pulmonary biomarker of possible, subtherapeutic the study including X, patients findings, powerful removing and program we to they our if top the clinical which doses sarcoidosis upon tapering the the steroid to work fundamental that By sarcoidosis X-milligram doses X regularly XXXX study on XXXX administers and X in sarcoidosis. that of Throughout models, clinical As we want trial steroid. we a pulmonary the and, in altogether the biomarkers, to to of cytokines are We current include in use, placebo. to From animal in that kilogram of think downregulated have as in note steroid was clinical some signal ILD, hypothesis the highlight mechanistic program lead relate a this steroid monthly in steroid. reported evolved encouraged our seen showed activity trial the a to single to down of dexamethasone, translational that ILD findings COVID-XX and it the which was a a evaluating compared design, established. the administered reduces highly comes compared while same it of COVID-XX trial of in When the in study. main in dose
XXXX literature of paper in SAA a that SAA, small that other the sarcoidosis, significant implications recent rather a Netherlands, levels We also expect of of the third just by importance not year. ILD. Lung Medical but that finding Center suggesting this at SAA leading to statistically in to marker in from in We study. report Excellence forward the this this growing Interstitial Disease of reiterate a excellent results XXXX reduction patients sarcoidosis, look also has which supports as published study evaluate the with in a of we pulmonary sarcoidosis, in quarter including had researchers fibrosing of the
turn renal, its is let's may where which breast, is expression with research NRPX our in to current target. continues potential Now linked different tumors, to solid in Antibodies cancers on pathways compelling is outcomes producing to In areas many selectively NRPX the inflammation. may resistance advance in to have include High can first therapeutic therapies. patient our lung antibody worsen potential pipeline, signaling various and In implicated. some aggressive few. drug upregulated name such NRPX that to a block therapeutic cases which is NRPX ILD. cancers, NRPX oncology of cancer, toward program, starting as NRPX a and
aggressive explore of we tumors, on continue a to the to of microenvironment the expression progression each of of wanted immune and of these As determine in tumor NRPX NRPX the cells. role on the certain role variety its we cells and
progression. poster cancer proliferation was that from the cells regulating MDSCs breast cell or suppressor macrophages immune mature implicated lines tumor-associated These Symposia, dendritic and virtual generated Further that T triple-negative cells showed expressed presented activation. MDSCs, on key in TAMs or Keystone included and recent cell TAMs myeloid-derived cells. at research demonstrated NRPX cancer Our and highly suppressed
key NRPX NRPX that support are a tumors have is target as regulation validation potent possibly their pleased further suppressive the time of These potential of cells regulating regulator the very NRPX the the through progression therapeutics, we're and highly for microenvironment, cells important findings provide expressed and So microenvironment. progression implicated immune of solid a as on to immune first of tumor tumor that cancer the for in demonstrated metastasis. the tumor of of
the at cancer, a meeting continued cancer of target selectively is solid medical breast Mercurio, lead ligands. lab NRPX we panel of that other the annual functionally breast has cancer progression are compelling from responsive in validated. As of specifically organoids to the NRPX shown on in aggressive to humanized other we and in the This highly collaboration we primary of to vitro interaction tumor at XXXX triple-negative available one our not blocks the where patients developed University showed its and tumor this explore the and and that of aggressive monoclonal models and is that XXXX chemotherapy of ILD to Arthur his school. many sensitivity various the IND-enabling to antibody XXXX candidate based to effects NRPX increased microenvironment tumor between implicated. at and human-derived potential expressed, scientific This data and look advance models role currently then, year our of distinct treatments. the one antibodies We we a and inhibitory have VEGF domains selected data NRPX becoming The in fully have and that presented models candidate. NRPX, in cancers Since certain of demonstrated been its AACR Dr. tumor Massachusetts increasingly with signaling importance in advisers generated VEGF, activity last extremely data an be where preclinical in
annual meeting. AACR will posters this Next month, we at X present year's
posters posters findings preclinical research AACR. presented regarding findings to poster our AACR lung these looking these cancer. at these last details cancer, we breast second forward the research from One new year builds at while the in We're presenting that providing of upon and in presents additional
related selected immune-needed discovery pursuing these fragrance we their role have in NK regarding findings. We new X tRNA demonstrate program, some AARS, X synthetases fragments AARS these the And and important January. innate transformative synthetases, at Finally, to Most utility tRNA and focus which research our synthetase in for demonstrate targets new discovered findings have activities information We the to update tRNA responses targets disease. our the maybe therapeutic receptor of we for I its forward AARS provide DARS. fibrosis pathways expect these cancer to receptor on particular, identified and DARS, in These tRNA to But has notably, key will pipeline, treat aTyr presented for now platform biology. SLAS recently our and a announced may a more at development ability from receptor on we biologic synthetase targets. look poster to these receptors relevance these binding that synthetases HARS, cell new in initially role We important determine X yielded further NK and SLAS potential future. exploring discovery cells wish is to disease vertical of to that tRNA have findings immune that targets in generate In pathways validate these DARS. therapeutics inflammation. and synthetases oncology. and targets of immune cells, new and findings in findings, to Based play biology presented the drug to
of compositions beginning promise a the and and unlocking As are patented. We aTyr's believe gene potential XX only from consists XXX portfolio covers intellectual protein this of all novel at families protein the over derivatives we tRNA reminder, biology platform. property with synthetase
like to financial So turn it Chief with to results. Broadfoot, Officer, Financial to that, over our our review I'd Jill
